Oropharyngeal squamous cell carcinoma (OPSCC) is the most common malignant tumor of the oropharynx (tonsil, tongue base, soft palate, posterior pharyngeal wall). The tonsil and tongue base are the most commonly involved sites. HPV-positive (p16+) OPSCC shows increasing incidence, constituting 70-80% of all OPSCC cases, and has significantly better prognosis than HPV-negative tumors (5-year survival 80-90% vs 40-50%). Cystic necrotic cervical LAP is a characteristic finding of HPV-positive tumors, and initial presentation with lymphadenopathy before primary tumor detection is common. AJCC 8th edition (2017) defined separate staging systems for HPV-positive and HPV-negative OPSCC — nodal staging is simplified in HPV-positive patients because prognosis is more dependent on HPV status. CT and MRI are complementary for primary tumor evaluation — CT superior for mandibular invasion and calcification, MRI for tongue base/soft tissue invasion and perineural spread. PET-CT has critical role in staging, treatment response, and unknown primary search.
Age Range
40-75
Peak Age
60
Gender
Male predominant
Prevalence
Common
HPV-positive OPSCC develops through transformation of palatine tonsil and tongue base lymphoid tissue crypt epithelium by high-risk HPV types (especially HPV-16). HPV oncoproteins E6 and E7 inactivate tumor suppressor proteins (p53 and Rb) — E6 degrades p53 via ubiquitin-proteasome pathway, E7 inhibits Rb rendering cell cycle uncontrolled. The susceptibility of tonsillar crypt epithelium to HPV infection stems from weak basement membrane integrity of the reticular epithelium. HPV-positive tumors typically show small primary + large cystic necrotic LAP pattern — this 'cystic LAP' is the pathognomonic finding of HPV-positive OPSCC. The cystic appearance results from keratin production and central necrosis by tumor cells in metastatic lymph nodes. On CT, cystic necrotic LAP shows thin wall and low-density center. On DWI, solid tumor component shows marked diffusion restriction — high cellularity restricts water diffusion movement. On MRI, tongue base invasion crossing midline is best evaluated on axial and coronal T2 sequences — critical for surgical planning.
Cystic necrotic LAP at cervical level II-III + infiltrative mass in tonsil or tongue base is the signature finding of HPV-positive oropharyngeal SCC. When cystic node is seen, HPV-positive OPSCC should be the primary consideration and oropharynx should be carefully evaluated.
Infiltrative enhancing soft tissue mass in tonsil or tongue base. Heterogeneous enhancement — may contain necrotic areas. Parapharyngeal fat plane infiltration indicates deep invasion. Prevertebral fascia and carotid sheath relationship critical for inoperability assessment.
Report Sentence
An infiltrative, heterogeneously enhancing soft tissue mass measuring ___ mm is identified in the right/left tonsil/tongue base, and oropharyngeal SCC should be the primary consideration.
Cystic necrotic cervical LAP — pathognomonic finding of HPV-positive OPSCC. Thin-walled lymph nodes with low-density center. Usually level II-III location. Presentation with LAP before primary tumor detection is common (unknown primary scenario).
Report Sentence
Cystic necrotic lymph nodes are identified at right/left cervical level II-III (largest ___ mm), consistent with nodal metastasis from HPV-positive oropharyngeal SCC; oropharyngeal primary tumor investigation is recommended.
Marked diffusion restriction on DWI — high signal in solid tumor component, ADC <1.0 × 10⁻³ mm²/s. Superior to CT for evaluating tongue base invasion crossing midline. In treatment response monitoring, ADC increase indicates complete response.
Report Sentence
The tongue base/tonsillar mass demonstrates marked diffusion restriction on DWI (ADC: ___ × 10⁻³ mm²/s) with invasion crossing/not crossing the midline.
High FDG uptake on PET-CT — primary tumor and nodal metastasis. SUVmax typically >5. In unknown primary scenario (cystic LAP + unknown primary), tonsil/tongue base FDG uptake localizes the primary tumor. Post-treatment PET-CT critical for response assessment.
Report Sentence
The oropharyngeal mass and cervical LAP demonstrate intense metabolic activity on FDG-PET (primary SUVmax: ___, nodal SUVmax: ___); TNM staging has been performed.
Mandibular cortical erosion — in advanced OPSCC, tumor adjacent to mandible may invade bone. CT is superior to MRI for bone erosion assessment. Dental CT or thin-section CT best evaluates cortical integrity. Mandibular invasion determines surgical approach (mandibulectomy need).
Report Sentence
Focal cortical erosion at the lingual cortex of the mandible is/is not identified and should be evaluated for surgical planning.
Criteria
p16 immunohistochemistry positive + HPV DNA/RNA positive. 70-80% of all OPSCC.
Distinct Features
Cystic necrotic LAP, small primary, younger patient, weak smoking/alcohol association. 5-year survival 80-90%. AJCC 8th edition separate staging.
Criteria
p16 negative. Smoking and alcohol associated. Older patient.
Distinct Features
Solid necrotic LAP (not cystic), larger primary tumor, worse prognosis. 5-year survival 40-50%.
Criteria
Cystic cervical LAP + primary tumor not found on clinical/CT.
Distinct Features
PET-CT can detect tonsil/tongue base primary with >90% sensitivity. If PET negative, tonsillectomy + tongue base mucosectomy recommended.
Distinguishing Feature
Lymphoma homogeneous, no bone erosion; SCC infiltrative, necrotic, cystic LAP
Distinguishing Feature
NPC nasopharyngeal location, fossa of Rosenmuller origin; OPSCC oropharynx (tonsil/tongue base), HPV associated
Distinguishing Feature
Adenoid hypertrophy symmetric, pediatric, nasopharynx; OPSCC asymmetric, infiltrative, oropharynx, adult
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralHPV-positive OPSCC treatment includes transoral robotic surgery (TORS) or primary chemoradiotherapy (cisplatin + IMRT). AJCC 8th edition uses separate staging for HPV-positive patients. De-intensification trials (less toxic treatment) are ongoing. HPV-negative OPSCC is treated with surgery + adjuvant chemoradiotherapy or primary chemoradiotherapy. Mandibular invasion requires composite resection (mandibulectomy + tumor). 12-week post-treatment PET-CT for response assessment is standard.
Treatment of HPV+ oropharyngeal SCC includes surgery (transoral robotic surgery — TORS) or chemoradiotherapy (cisplatin-based). Five-year survival is 80-90% for HPV+ and 40-50% for HPV-negative tumors. TNM staging (AJCC 8th edition) uses separate staging systems for HPV+ and HPV-negative tumors. De-intensification trials (less toxic treatment) for HPV+ patients are ongoing.